NASDAQ:CVKD Cadrenal Therapeutics (CVKD) Stock Price, News & Analysis → Top Project Outperforms BTC in 2023… (From Crypto 101 Media) (Ad) Free CVKD Stock Alerts $0.61 -0.03 (-4.64%) (As of 10:32 AM ET) Add Compare Share Share Today's Range$0.60▼$0.6450-Day Range$0.56▼$1.8252-Week Range$0.40▼$3.14Volume23,862 shsAverage Volume348,496 shsMarket Capitalization$9.77 millionP/E RatioN/ADividend YieldN/APrice Target$3.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Cadrenal Therapeutics alerts: Email Address Cadrenal Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside473.5% Upside$3.50 Price TargetShort InterestHealthy0.40% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.43Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.34) to ($0.31) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.34 out of 5 starsMedical Sector435th out of 939 stocksPharmaceutical Preparations Industry204th out of 433 stocks 3.5 Analyst's Opinion Consensus RatingCadrenal Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.50, Cadrenal Therapeutics has a forecasted upside of 473.5% from its current price of $0.61.Amount of Analyst CoverageCadrenal Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.40% of the float of Cadrenal Therapeutics has been sold short.Short Interest Ratio / Days to CoverCadrenal Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cadrenal Therapeutics has recently increased by 204.17%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCadrenal Therapeutics does not currently pay a dividend.Dividend GrowthCadrenal Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CVKD. Previous Next 2.5 News and Social Media Coverage News SentimentCadrenal Therapeutics has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Cadrenal Therapeutics this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for CVKD on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.MarketBeat Follows6 people have added Cadrenal Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cadrenal Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders58.12% of the stock of Cadrenal Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 7.92% of the stock of Cadrenal Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cadrenal Therapeutics are expected to grow in the coming year, from ($0.34) to ($0.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cadrenal Therapeutics is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cadrenal Therapeutics is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCadrenal Therapeutics has a P/B Ratio of 1.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)Watch my video for all of the details About Cadrenal Therapeutics Stock (NASDAQ:CVKD)Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.Read More CVKD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CVKD Stock News HeadlinesMarch 18, 2024 | americanbankingnews.comEquities Analysts Set Expectations for Cadrenal Therapeutics, Inc.'s FY2028 Earnings (NASDAQ:CVKD)March 14, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Cadrenal Therapeutics, Inc. (CVKD), Protara Therapeutics (TARA) and Spruce Biosciences (SPRB)March 28, 2024 | Crypto 101 Media (Ad)Top Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.March 11, 2024 | finanznachrichten.deCadrenal Therapeutics, Inc.: Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate UpdateMarch 11, 2024 | finance.yahoo.comCadrenal Therapeutics Provides Fourth Quarter 2023 Corporate UpdateFebruary 26, 2024 | prnewswire.comCadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) ConferenceFebruary 14, 2024 | morningstar.comCadrenal Therapeutics Inc CVKDFebruary 8, 2024 | finanznachrichten.deCadrenal Therapeutics, Inc.: Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal TrialMarch 28, 2024 | Crypto 101 Media (Ad)Top Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.February 8, 2024 | finance.yahoo.comCadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal TrialJanuary 31, 2024 | finance.yahoo.comCadrenal Therapeutics Highlights Publication of Peer-Reviewed Article Supporting Need for New Anticoagulation Therapy for Patients with Certain Medical ConditionsJanuary 30, 2024 | finance.yahoo.comHere's Why We're Not Too Worried About Cadrenal Therapeutics' (NASDAQ:CVKD) Cash Burn SituationJanuary 24, 2024 | finance.yahoo.comCadrenal Therapeutics to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024January 4, 2024 | finance.yahoo.comCadrenal Therapeutics to Present at the Biotech Showcase on January 8, 2024 Alongside the J.P. Morgan Annual Healthcare ConferenceDecember 19, 2023 | benzinga.comCadrenal Therapeutics Stock (NASDAQ:CVKD), Analyst Ratings, Price Targets, PredictionsDecember 11, 2023 | uk.finance.yahoo.comCadrenal Therapeutics, Inc. (CVKD)November 30, 2023 | finance.yahoo.comCadrenal Therapeutics to Present at the NobleCon 19 Conference on December 4, 2023November 21, 2023 | msn.comHC Wainwright & Co. Initiates Coverage of Cadrenal Therapeutics (CVKD) with Buy RecommendationNovember 9, 2023 | msn.comCadrenal Therapeutics reports Q3 resultsNovember 9, 2023 | finance.yahoo.comCadrenal Therapeutics Provides Third Quarter 2023 Corporate UpdateOctober 9, 2023 | finance.yahoo.comCadrenal Therapeutics to Participate in the Lytham Partners Fall 2023 Investor ConferenceSeptember 5, 2023 | finance.yahoo.comCadrenal Therapeutics Highlights Additional Need for a New Vitamin K Antagonist (Tecarfarin) Following Updates from the Recent European Society of Cardiology CongressAugust 30, 2023 | finance.yahoo.comCadrenal Therapeutics Expands Evaluation of Tecarfarin for Patients with Antiphospholipid Syndrome (APS)August 28, 2023 | finance.yahoo.comCadrenal Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 18, 2023 | seekingalpha.comCVKD Cadrenal Therapeutics, Inc.August 10, 2023 | finance.yahoo.comCadrenal Therapeutics Provides Second Quarter 2023 Corporate UpdateAugust 1, 2023 | finance.yahoo.comCadrenal Therapeutics Expands Focus for Tecarfarin to Patients with Implanted Medical Devices for Heart DiseasesSee More Headlines Receive CVKD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cadrenal Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today3/28/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CVKD CUSIPN/A CIK1937993 Webwww.cadrenal.com Phone904-300-0701FaxN/AEmployees3Year FoundedN/APrice Target and Rating Average Stock Price Target$3.50 High Stock Price Target$4.00 Low Stock Price Target$3.00 Potential Upside/Downside+446.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,360,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-128.67% Return on Assets-117.76% Debt Debt-to-Equity RatioN/A Current Ratio10.27 Quick Ratio10.27 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.59 per share Price / Book1.08Miscellaneous Outstanding Shares16,010,000Free Float6,704,000Market Cap$10.25 million OptionableNot Optionable Beta1.24 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Quang X. Pham (Age 59)Chairman & CEO Comp: $822.17kMr. Matthew K. Szot CPA (Age 50)CPA, Co-Founder & CFO Comp: $359.61kDr. Douglas W. Losordo FACC (Age 66)FAHA, M.D., Chief Medical Officer Comp: $23.36kMr. Jeff ColeChief Operating OfficerKey CompetitorsASLAN PharmaceuticalsNASDAQ:ASLNAkari TherapeuticsNASDAQ:AKTXMonopar TherapeuticsNASDAQ:MNPRHepion PharmaceuticalsNASDAQ:HEPAGalera TherapeuticsNASDAQ:GRTXView All CompetitorsInsiders & InstitutionsArmistice Capital LLCSold 568,000 shares on 2/13/2024Ownership: 3.182%John Raymond MurphyBought 17,331 shares on 10/4/2023Total: $12,131.70 ($0.70/share)Quang X PhamBought 70,000 shares on 9/1/2023Total: $63,700.00 ($0.91/share)View All Insider TransactionsView All Institutional Transactions CVKD Stock Analysis - Frequently Asked Questions Should I buy or sell Cadrenal Therapeutics stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cadrenal Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CVKD shares. View CVKD analyst ratings or view top-rated stocks. What is Cadrenal Therapeutics' stock price target for 2024? 2 analysts have issued twelve-month price objectives for Cadrenal Therapeutics' stock. Their CVKD share price targets range from $3.00 to $4.00. On average, they anticipate the company's stock price to reach $3.50 in the next year. This suggests a possible upside of 473.5% from the stock's current price. View analysts price targets for CVKD or view top-rated stocks among Wall Street analysts. How have CVKD shares performed in 2024? Cadrenal Therapeutics' stock was trading at $0.7399 at the beginning of 2024. Since then, CVKD stock has decreased by 17.5% and is now trading at $0.6103. View the best growth stocks for 2024 here. Are investors shorting Cadrenal Therapeutics? Cadrenal Therapeutics saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 21,900 shares, an increase of 204.2% from the February 29th total of 7,200 shares. Based on an average trading volume of 340,600 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.4% of the shares of the company are short sold. View Cadrenal Therapeutics' Short Interest. When is Cadrenal Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our CVKD earnings forecast. When did Cadrenal Therapeutics IPO? Cadrenal Therapeutics (CVKD) raised $7 million in an initial public offering on Friday, January 20th 2023. The company issued 1,400,000 shares at $5.00 per share. Who are Cadrenal Therapeutics' major shareholders? Cadrenal Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (3.18%). Insiders that own company stock include John Raymond Murphy and Quang X Pham. View institutional ownership trends. How do I buy shares of Cadrenal Therapeutics? Shares of CVKD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CVKD) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryUrgent: Protect Your Investments from a Chinese InvasionBehind the MarketsSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cadrenal Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.